SCI — Investor Presentation 2014

Sep 19, 2014

SCI PHARMTECH, ING.

簡報

procedure Thainform Forwardterium Leola

All-HescoryList.Count > 0 these Forwardten inn, Enchind in Michon

Xol ardAckion, Enabled a False and r

CLOSE EXOTORIC + Teres, NYL !! Store population Prosentern Mobile which I is coast plasp: Dispatch, var MII Reading at OleVariable r-way

d destoryTodes + 01 MALDE HARGOLYLAST COMME . HAR I dioryLift Delate Office or 97 Highlip Ladas in Ristory List. Add

DES

RicertyTodes is Newtodes: ar brownsteads then hegin

Doctor Course I'm Falue.

Mel Andex ; a UEZ; Ituna, Index02

AE MANDICON - - 1 About

UP J. ftems, Promer (0, U914

員工數Employee:202 設立日期:中華民國七十六年九月十八日 Date of establishment: Sep. 18, 1987 資本額Capital:新台幣697佰萬元(NTD 697mn) 營業項目Business: 原料藥API(33.85%) 中間體Intermediate(54.82%) 特用化學品 Custom-made chemicals(11.33%)

公司概況Outline

	Y2013	Y2014 to date
歐 洲Europe	36.01%	43.37%
美 洲America	22.80%	23.07%
亞 洲Asia	24.00%	17.31%
國 內Taiwan	17.19%	15.25%
洲Australia 澳	0.00%	1.00%
計Total 合	100.00%	100.00%

Unit: K NTD

	2013	2014 to date
營收Sales	1,292,734	920,374
營業成本COGS	(895,753)	(620,173)
毛利Gross Profit	396,981	300,201
毛利率 GP Ratio	30.7%	32.6%
營業費用Operating Expenses	(191,122)	(116,618)
營業利益Operating Income	205,859	183,583
營業外損益Non-Operating In/Ex	(12,079)	35,543
稅前淨利 Net Profit before Tax	193,780	219,126
所得稅Income Tax	(33,842)
本期淨利Net Profit after Tax	159,938

產品組合-Products

Y2011	$\frac{0}{0}$
Di-VaNa	24.51%
PGA	17.65%
V.A.	13.76%
PPON	10.70%
M85	5.25%
Pent-2	3.73%
DBS	3.08%
M115	2.55%
M74	2.31%
NBE	$1.87\%$
Total	85.40%

Y2011	%	Y2012	%	Y2013	%
Di-VaNa	24.51%	V.A.	18.66%	PGA	18.31%
PGA	17.65%	PGA	16.61%	Di-VaNa	16.92%
V.A.	13.76%	Di-VaNa	15.97%	S20/38	8.39%
PPON	10.70%	PPON	7.88%	V.A.	8.23%
M85	5.25%	Pent-2	4.78%	LPF.Na	6.58%
Pent-2	3.73%	5-HMT	4.33%	PPON	6.53%
DBS	3.08%	M85	3.89%	5-HMT	4.51%
M115	2.55%	DBS	2.73%	PEB.Na	3.98%
M74	2.31%	M115	2.59%	NaVa	3.34%
NBE	1.87%	M74	2.18%	DBS	2.63%
Total	85.40%	Total	79.62%	Total	79.42%

No.	Product	$\frac{0}{0}$	Sales (NT\$)
1	PGA	16.42%	171,211,625
$\overline{2}$	S20/38	11.80%	123,012,851
3	LPF.Na	8.02%	83,648,469
$\overline{\mathbf{4}}$	Di-VANa	7.16%	74,679,509
5	V.A.	6.78%	70,674,609
6	DBS	5.43%	56,637,640
$\overline{\mathbf{7}}$	PEB.Na	4.32%	45,009,722
8	NaVA	3.66%	38, 161, 228
9	5-HMT	3.54%	36,882,944
10	PPON	3.52%	36,718,089

SCI

NaVa

V DEDPM.

Pyrogallolaldehyde ( PGA) - Benserazide

治療帕金森氏症之中間體 Intermediate for Parkinson's Disease

2個客戶 2 customers

2014 sales: 171 M

Anti-inflammatory (Loxoprofen sodium) 2012年銷售5佰萬 5 mn sales in 2012 2013年銷售85佰萬 85 mn sales in 2013 2014 sales:83.6 M 日本市場200-300公噸, 180美金/公斤 Japan market:200-300MT at USD 180/kg

S20/38

2014 sales:123M

產品介紹Product

Valproic Acid (VA)

20個客戶 20 customers 2014 sales: 70.7 M

Pentobarbital Sodium

• 鎮定安眠用之原料藥 API used as calmative
• 4個客戶 4 customers
• 2014 sales:45M

Sodium Valproate (NaVA)

22 客戶 22 customers 2014 sales: 38M

5-HMT – Ritonavir,Lopinavir

愛滋病藥物中間體 For AIDS treatment 2014 sales: 36.9M

Antidepressant (Duloxetine) 2013年底專利到期 Patent expired in the end of 2013 10個客戶 10 customers

Antidepressant (S-MMAA) Duloxetine之中間體 intermediate of Duloxetine 2014 sales: 12.5 M

• 5t: 15.3m sales
• Hydroxychloroquine sulfate: 12 m sales
• Propafenone: 10 m sales
• Cyclophosphamide: 1.4 m sales
• Lorcaserin

GMP Status(GMP現況)

	CGMP	CEP	DMF	MF	DMF
API	certified	(EDQM)	(USA)	(Japan)	(Canada)
	(TFDA)
Valproic Acid (*)	2003	2004	2003	2008	2008
Allopurinol	2004	2003	2011
Probucol	2004		2004
Sodium Valproate	2004	2006
Divalproex Sodium (**)	2005		2005		2010
Bisoprolol Fumarate	2006
Pentobarbital Sodium	2009	2 011
Propafenone Hydrochloride	2010	2012	2010	2012	2012
Methylphenidate HCl	2 011	2014
Duloxetine Hydrochloride	2012	2014	2010/2011
Thiopental acid	2012
Loxoprofen Sodium Hydrate	2012			2011
Articaine Hydrochloride	2013	2014
Hydroxychloroquine Sulfate	2014		2014
Clindamycin Palmitate HCl			2011
Cyclophosphamide			2012

(*)(**) FDA inspection: Nov. 2005 / April 2012, (*) EDQM inspection: Nov. 2010

敬 請 指 教